Overview

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals